Remove

PTC\SB(08x (08-03)
Approved for use through 07/31/2006 OMB 085-1-2031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE
d to a collection of information unless it contains a valid OMB control number.

	Application Number			
	Filing Date			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Kımim		imasa Senba	
(Not for submission under 37 CFR 1.99)	Art Unit			
,	Examiner Name			
	Attorney Docket Numb	er	09792909-6787	

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	5686849		1997-1	1-11	Burzio				
If you wis	h to a	i dd additional U.S. Pater	nt citatio	n inform	ation pl	l lease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Relev	s,Columns,Lines wh ant Passages or Re es Appear	ere levant
	1									
If you wis	h to a	dd additional U.S. Publi						d butto		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lin where Relevant Passages or Releva Figures Appear	74
	1	11-308097	JP			1999-11-05	Sony Corp			V
	2	11-232-795	JP			1999-08-27	Matsushita Electric Co Ltd	Ind		V
	3	08-279747	JP			1996-10-22	CSELT SPA			V

Application Number | Filing Date | Filing Date | Filing Date | First Named Inventor | Kemansa Seriba | Art Unit | Filing Date | First Named Inventor | Kemansa Seriba | Art Unit | Filing Date | First Named Inventor | Kemansa Seriba | Art Unit | Filing Date | First Named Inventor | Kemansa Seriba | Art Unit | Filing Date | F

	4	EP 0	732 830	EP		1996-09-18	CSELT			
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
	NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), ittle of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								Τs	
	1 International Search Report dated May 31, 2005									
If you wish to add additional non-patent literature document citation information please click the Add button Add										
EXAMINER SIGNATURE										
Examiner	Signa	ture					Date Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See for Godes of USPTO Platent Documents at week_USPTO.060 or MPEP 901.04. * Extent office that issued the document, by the two-teles code (WIPO Standard STI3,). **Explaines platent document, by an exclusion or the paper of the relign or the Emperor must provide the sent in runber of the paper of the relign or the Emperor must provide the sent in runber of the paper of the relign of the Emperor must provide the sent in runber of the sent of the document by the appropriate symbols as endocated on the document under WIPO Standard ST.16 if possible. **Applicant is to place a check must here if the provided in the sent of the

Application Number Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 199) At Unit Examiner Name Attorney Docket Number | 007902009-0787

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CPR 197(eVI).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the contraction of the

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Diagon one 37 CER 1 07 and 1 98 to make the appropriate colortion(c)

□ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/David R. Metzger/	Date (YYYY-MM-DD)	2006-08-28						
Name/Print	David R. Metzger	Registration Number	32919						

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (ii.e., GSA).
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

APPARATUS

APPLICANT(S): Kimimasa Senba DOCKET NO.: 09792909-6787 SERIAL NO.: Unknown GROUP ART UNIT: Unknown

DATE FILED: EXAMINER: Unknown INVENTION: PHASE LOCKED CIRCUIT AND INFORMATION

Mail Stop PCT Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

REPRODUCTION

SIR

In accordance with the provisions of 37 C.F.R. § 1.56, Applicants request that citation and examination of the references identified on the attached PTO-SB08A, form, in accordance with 37 C.F.R. § 1.98, be made during the course of examination of the above-referenced application for United States Letters Patent. Foreign Patent Document Cite Nos. 1 and 2 are mentioned in the specification and their relevance is as stated therein. Foreign Patent Document Cite Nos. 3 and 4 and U.S. Patent Cite No. 1 were cited in a Search Report issued in connection with Japanese Serial No. PCT/IP2005:003154. Copies of the references and the search report are attached.

Respectfully submitted by,

/David R. Metzger/ (Reg. 32,919) David R. Metzger

SONNENSCHEIN NATH & ROSENTHAL LLP P.O. Box 061080

Wacker Drive Station, Sears Tower Chicago, IL 60606-1080 Telephone: 312/876-8000 Fax: 312/876-7934